STOCKHOLM, SE / ACCESSWIRE / June 8, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the …
STOCKHOLM, SE / ACCESSWIRE / June 8, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad
portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company will participate
at Småbolagsdagarna in Stockholm, Sweden, on June 13 at 14:20 CET. CEO Martin Jönsson will present the latest development of the company, including the recently presented positive phase II results
with ACD440 in neuropathic pain.
Småbolagsdagarna will be held at Birger Jarl Konferens, Birger Jarlsgatan 61 A in Stockholm, Sweden, on June 12-14, and is organized by Aktiespararna, the world‘s largest member organization for
private individuals who save in shares and funds.